ES2096867T3 - Uso de antagonistas competitivos del receptor de nmda en el tratamiento de la incontinencia urinaria. - Google Patents

Uso de antagonistas competitivos del receptor de nmda en el tratamiento de la incontinencia urinaria.

Info

Publication number
ES2096867T3
ES2096867T3 ES93305762T ES93305762T ES2096867T3 ES 2096867 T3 ES2096867 T3 ES 2096867T3 ES 93305762 T ES93305762 T ES 93305762T ES 93305762 T ES93305762 T ES 93305762T ES 2096867 T3 ES2096867 T3 ES 2096867T3
Authority
ES
Spain
Prior art keywords
urinary incontinence
treatment
nmda receptor
competitive antagonists
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93305762T
Other languages
English (en)
Inventor
Karl Bruce Thor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2096867T3 publication Critical patent/ES2096867T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION PROVEE UN METODO DE TRATAR INCONTINENCIA URINARIA DE IMPULSO MOTOR EN UN MAMIFERO LA CUAL COMPRENDE ADMINISTRAR UNA CANTIDAD EFECTIVA DE UN ANTAGONISTA NMDA COMPETITIVO, TAL COMO ACIDO (3S,4AR,6S,8AR) FONIOMETILO) 3 8AR) ISOQUINOLINACARBOXILICO, O ACIDO (2R, 4S)
ES93305762T 1992-07-24 1993-07-22 Uso de antagonistas competitivos del receptor de nmda en el tratamiento de la incontinencia urinaria. Expired - Lifetime ES2096867T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/919,480 US5192751A (en) 1992-07-24 1992-07-24 Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence

Publications (1)

Publication Number Publication Date
ES2096867T3 true ES2096867T3 (es) 1997-03-16

Family

ID=25442169

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93305762T Expired - Lifetime ES2096867T3 (es) 1992-07-24 1993-07-22 Uso de antagonistas competitivos del receptor de nmda en el tratamiento de la incontinencia urinaria.

Country Status (9)

Country Link
US (1) US5192751A (es)
EP (1) EP0580429B1 (es)
JP (1) JPH06183975A (es)
AT (1) ATE147977T1 (es)
CA (1) CA2100950A1 (es)
DE (1) DE69307617T2 (es)
DK (1) DK0580429T3 (es)
ES (1) ES2096867T3 (es)
GR (1) GR3023032T3 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594007A (en) * 1991-04-18 1997-01-14 Pfizer Inc. Method for treating spinal cord trauma with phenolic 2-piperidino-1-alkanols
US5436255A (en) * 1992-07-23 1995-07-25 Pfizer Inc. Method of treating diseases susceptable to treatment by blocking NMDA-receptors
US5192751A (en) * 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5498610A (en) * 1992-11-06 1996-03-12 Pfizer Inc. Neuroprotective indolone and related derivatives
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
BR9408506A (pt) * 1994-01-31 1997-08-05 Pfizer Compostos neuroprotetores
RU2139857C1 (ru) * 1994-08-18 1999-10-20 Пфайзер Инк. Производные 3-(пиперидинил-1)-хроман-4,7-диола и 1-(4-гидроксифенил)-2-(пиперидинил-1)-алканола, фармацевтическая композиция и способ связывания nmda рецептора
JP3348230B2 (ja) 1995-03-03 2002-11-20 アルゴス ファーマシューティカル コーポレーション 尿失禁の治療用のデキシトルメトルファン又はデキシトルオルファンの使用
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ZA9610736B (en) 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
TW427978B (en) * 1996-02-03 2001-04-01 Hoffmann La Roche Tetrahydroisoquinoline derivatives
US5880138A (en) * 1996-10-01 1999-03-09 Eli Lilly And Company NMDA receptor selective antagonists
US7449192B2 (en) 1997-07-15 2008-11-11 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction
US7455845B2 (en) 1997-07-15 2008-11-25 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure
ATE320815T1 (de) 1997-07-15 2006-04-15 Univ Colorado Verwendung einer neurotoxintherapie zur behandlung von prostata erkrankungen
US7470431B2 (en) 1997-07-15 2008-12-30 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer
US9066943B2 (en) 1997-07-15 2015-06-30 The Regents Of The University Of Colorado Use of botulinum toxin therapy for treatment of urological neurological conditions
PE20000728A1 (es) 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
ATE305788T1 (de) * 1999-07-01 2005-10-15 Pharmacia & Upjohn Co Llc (s,s)-reboxetin zur behandlung von inkontinenz
JP2005506292A (ja) * 2001-03-08 2005-03-03 エモリー　ユニバーシティ ｐＨに依存するＮＭＤＡレセプターアンタゴニスト
KR20100045983A (ko) 2007-06-29 2010-05-04 에모리 유니버시티 신경보호를 위한 ｎｍｄａ 수용체 길항물질
CN122422302A (zh) * 2023-12-14 2026-07-17 斯莱普泰(上海)生物医药科技有限公司 Nmda受体拮抗剂及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968678A (en) * 1988-02-19 1990-11-06 Eli Lilly And Company Tetrazole excitatory amino acid receptor antagonists
US4902695A (en) * 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5192751A (en) * 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence

Also Published As

Publication number Publication date
GR3023032T3 (en) 1997-07-30
CA2100950A1 (en) 1994-01-25
EP0580429A1 (en) 1994-01-26
EP0580429B1 (en) 1997-01-22
DE69307617T2 (de) 1997-05-28
JPH06183975A (ja) 1994-07-05
US5192751A (en) 1993-03-09
DK0580429T3 (da) 1997-07-14
ATE147977T1 (de) 1997-02-15
DE69307617D1 (de) 1997-03-06

Similar Documents

Publication Publication Date Title
GR3023032T3 (en) Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
NL300174I1 (nl) Toepassing van venlafaxine of een aryloxypropaanamineverbinding voor de bereiding van een geneesmiddel voor de behandeling van incontinentie.
ES2115691T3 (es) Derivados de benzotiepina, benzotiopirano y benzotiofeno, su obtencion y utilizacion de los mismos como farmacos.
ATE154880T1 (de) Multifunktionelle pharmazeutische verbindungen und verfahren zu ihrer verwendung
DK0411668T3 (da) Central-cholecystokinin-antagonister til behandling af psykiatriske forstyrrelser
MX9200361A (es) Nuevo uso del antagonista de adenosina.
FI921345A0 (fi) Piperidinderivat.
ES2133324T3 (es) Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso.
DK0432117T3 (da) Farmaceutisk præparat til behandling af inflammation
DE69223736D1 (de) Acridine-1,8-Dionderivate als therapeutisches Mittel
TR199700711T1 (xx) Ciltten ge�erek v�cuda giren form�lasyon.
DE69330754D1 (de) 2,5-DIOXO-2,5-DIHYDRO-1H-BENZ[b]AZEPINE ALS NMDA REZEPTOR ANTAGONISTEN
MX9205549A (es) Metodo para el tratamiento de vih.
HU9700661D0 (en) Use of alpha-1-adrenoreceptor antagonists for profilacting and treating cancer
ATE103182T1 (de) Antimikrobielle zusammensetzungen.
ATE145911T1 (de) Inositol-phosphat-analog als kalzium- antagonistische substanz
DE69231263D1 (de) Calcitonin enthaltende pharmazeutische Zusammensetzungen
ES2019262A4 (es) Procedimiento para el tratamiento biologico de nitratos disueltos
WO1992007564A3 (en) Method of treating demyelinating disease
DE69009765D1 (de) Kynurensäurederivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ES2097277T3 (es) Uso de un compuesto ester tiol-s-(2-dietilaminoetilico) para la preparacion de un medicamento para el tratamiento de la incontinencia neuro-muscular.
EP0412941A3 (en) Phospholipids for the treatment of multiple sclerosis
ITRM920516A1 (it) Composizione e suo uso per il trattamento terapeutico di affezioni dermatitiche, particolarmente la psoriasi.
MX9205778A (es) Agente terapeutico.
ES1026191Y (es) Dispositivo de regulacion perfeccionado para la plataforma auxiliar de mesillas clinicas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 580429

Country of ref document: ES